Abbott Laboratories
105.23USD
-0.2900 (-0.27%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 43.7B | 40.1B | 42.0B | 44.3B | 50.3B | 54.6B |
| Q1 | 11.9B | 9.7B | 10.0B | 10.4B | 11.2B | — |
| Q2 | 11.3B | 10.0B | 10.4B | 11.1B | — | — |
| Q3 | 10.4B | 10.1B | 10.6B | 11.4B | 13.0B | — |
| Q4 | 10.1B* | 10.2B* | 11.0B* | 11.5B* | 13.5B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 3.91 | 3.26 | 7.64 | 3.72 | 5.52 | 6.06 |
| Q1 | 1.37 | .750 | .700 | .760 | .610 | — |
| Q2 | 1.14 | .780 | .740 | 1.01 | — | — |
| Q3 | .810 | .820 | .940 | .940 | 1.42 | — |
| Q4 | .586* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| .911* |
| 5.28* |
| 1.02* |
| 1.64 |
| — |